Skip to main content
Menu
detecting-total1920x640
Literature - Publication Review

Advancing α-Synuclein pathology insights for targeted Parkinson’s disease therapies

This publication review is based on recent research focused on characterizing α -synuclein pathology in preclinical models, employing AlphaLISA™ SureFire® Ultra assays to measure total and phosphorylated S129 α-synuclein levels, along with the BioLegend LEGEND MAX™ α-Synuclein Aggregate ELISA assay.

This publication review details:

  • Detection of α-synuclein and pS129 in mouse and human samples
  • Validated performance across tissues and cell models with minimal background
  • Link between phosphorylation and aggregation in diseased brain regions
  • Scalable platform for biomarker discovery and therapeutic research in synucleinopathies

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Advancing α-Synuclein pathology insights for targeted Parkinson’s disease therapies

Download Literature - Publication Review

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.

Revvity AI Assistant Beta